Pfizer’s Paxlovid Misses On Prevention, But Impact Limited
A Phase II/III trial testing Paxlovid as a preventative treatment for COVID-19 failed to show a statistically significant efficacy benefit.
You may also be interested in...
The company announced updated results from a standard-risk study, which it will include in its overall new drug application, but whether Paxlovid will see approval or uptake in that group is another question.
Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.
The company could reach $100bn in revenues in 2022 for the first time, powered by Comirnaty and Paxlovid; actual sales for the COVID-19 products are likely to go higher based on supply contracts.